Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India by Kiran Mazumdar-Shaw, the founder. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries [no proof provided] across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets [provide reference]. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon.
FlandersBio, founded in 2004, is the networking organisation for the life sciences sector in Flanders and represents and supports close to 300 member companies. The key strategic objectives of FlandersBio are knowledge exchange and valorisation, human capital development, internationalization of the cluster activities and visibility, familiarization of the public with products derived from the sector and the further development of a supportive environment for the members of FlandersBio.
David A. Zarling is a co-founder, president and CEO of Colby Pharmaceutical Company and an oncology drug development scientist and entrepreneur. Zarling also has been a part of teams that successfully licensed technology to start-up companies, one of which subsequently achieved significant market capitalization.
Jan-Åke Gustafsson is a Swedish scientist and professor in Biology, Biochemistry and Medical Nutrition. When he decided to move to Houston, Texas, USA, in 2008, the State of Texas decided to give a major US $ 5.5 million research grant to the University of Houston, enabling the establishment of the Center of Nuclear Receptors and Cell Signaling under the leadership of Jan-Åke Gustafsson. The grant was announced at a February 5, 2009, press conference by Rick Perry, Governor of Texas and running for the Republican nomination for President of the United States in the 2012 presidential election.
Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.
Jalkanen is a Finnish surname. Notable people with the surname include:
Christoph Westphal, M.D., Ph.D., is a biomedical entrepreneur.
David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland. Therapeutic opportunities are identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Sirpa Jalkanen is a Finnish scientist, working in the field of biomedical and clinical medicine, at the University of Turku in Finland.
John Monahan is an Irish-born biochemist and CEO of biotechnology and gene therapy companies in the United States.
Kevin Donald Lustig is a male American scientist and entrepreneur and founder of three life science companies: the pharmaceutical company Kalypsys in 2001; the online research marketplace Scientist.com in 2007; and the non-profit lab incubator Bio, Tech and Beyond in 2013.
Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.
Pekka Sillanaukee is a Finnish health technology entrepreneur. Pekka graduated as an organic chemist in 1989, he became a Ph.D. in 1992 and was appointed Docent of Medical Biochemistry at the Faculty of Medicine of the University of Tampere in 1993. Pekka has been a co-author of approximately 120 scientific original articles, reviews or summaries. His scientific work has focused on clinical and medical biochemistry, alcohol, brain and cardiovascular related diseases, and development of laboratory-diagnostic tests and processes. He also has four international patents.
Erik Gatenholm is a Swedish-American entrepreneur. He is credited with creating the world's first universal bio-ink.
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.
